» Articles » PMID: 22507972

Endothelial-dependent Vasomotion in a Coronary Segment Treated by ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System is Related to Plaque Composition at the Time of Bioresorption of the Polymer: Indirect Finding of Vascular Reparative...

Abstract

Aims: To analyse the vasoreactivity of a coronary segment, previously scaffolded by the ABSORB bioresorbable vascular scaffold (BVS) device, in relationship to its intravascular ultrasound-virtual histology (IVUS-VH) composition and reduction in greyscale echogenicity of the struts. Coronary segments, transiently scaffolded by a polymeric device, may in the long-term recover a normal vasomotor tone. Recovery of a normal endothelial-dependent vasomotion may be enabled by scaffold bioresorption, composition of the underlying tissue, or a combination of both mechanisms.

Methods And Results: All patients from the ABSORB Cohort A and B trials, who underwent a vasomotion test and IVUS-VH investigation at 12 and 24 months, were included. Acetylcholine (Ach) and nitroglycerin were used to test either the endothelial-dependent or -independent vasomotion of the treated segment. Changes in polymeric strut echogenicity-a surrogate for bioresorption-IVUS-VH composition of the tissue underneath the scaffold and their relationship with the pharmacologically induced vasomotion were all evaluated. Overall, 26 patients underwent the vasomotion test (18 at 12 and 8 at 24 months). Vasodilatory response to Ach was quantitatively associated with larger reductions over time in polymeric strut echogenicity (y= -0.159x- 6.85; r= -0.781, P< 0.001). Scaffolded segments with vasoconstriction to Ach had larger vessel areas (14.37 ± 2.50 vs. 11.85 ± 2.54 mm(2), P= 0.030), larger plaque burden (57.31 ± 5.96 vs. 49.09 ± 9.10%, P= 0.018), and larger necrotic core (NC) areas [1.39 (+1.14, +1.74) vs. 0.78 mm(2) (+0.20, +0.98), P= 0.006] compared with those with vasodilation.

Conclusion: Vasodilatory response to Ach, in coronary segments scaffolded by the ABSORB BVS device, is associated with a reduction in echogenicity of the scaffold over time, and a low amount of NC. In particular, the latter finding resembles the behaviour of a native coronary artery not caged by an intracoronary device.

Citing Articles

Optimal lesion preparation before implantation of a Magmaris bioresorbable scaffold in patients with coronary artery stenosis: Rationale, design and methodology of the OPTIMIS study.

Hansen K, Maehara A, Noori M, Troan J, Fallesen C, Hougaard M Contemp Clin Trials Commun. 2024; 38:101260.

PMID: 38384894 PMC: 10879808. DOI: 10.1016/j.conctc.2024.101260.


Bone morphogenetic protein-4 system expression in human coronary artery endothelial and smooth muscle cells under dynamic flow: effect of medicated bioresorbable vascular scaffolds at low and normal shear stress.

Cabiati M, Giacomarra M, Fontanini M, Cecchettini A, Pelosi G, Vozzi F Heart Vessels. 2022; 37(12):2137-2149.

PMID: 35857064 DOI: 10.1007/s00380-022-02140-w.


Advantages and prospects of optical coherence tomography in interventional therapy of coronary heart disease (Review).

Wang J, Yuan S, Qi J, Zhang Q, Ji Z Exp Ther Med. 2022; 23(4):255.

PMID: 35261627 PMC: 8855506. DOI: 10.3892/etm.2022.11180.


Optical coherence tomography tissue coverage and characterization at six months after implantation of bioresorbable scaffolds versus conventional everolimus eluting stents in the ISAR-Absorb MI trial.

Rai H, Alfonso F, Maeng M, Bradaric C, Wiebe J, Cuesta J Int J Cardiovasc Imaging. 2021; 37(10):2815-2826.

PMID: 34420177 PMC: 8494721. DOI: 10.1007/s10554-021-02251-x.


Very late vasomotor responses and gene expression with bioresorbable scaffolds and metallic drug-eluting stents.

Koh J, Gogas B, Kumar S, Benham J, Sur S, Spilias N Catheter Cardiovasc Interv. 2021; 98(4):723-732.

PMID: 34164905 PMC: 8545466. DOI: 10.1002/ccd.29819.